Opdivo and Yervoy

Active substance nivolumab and ipilimumab
Holder Bristol-Myers Squibb SA/NV
Status Running
Indication First line treatment of adult patients with unresectable malignant pleural mesothelioma
Public documents Approbation
  Information for the patient
  Informed consent
Last update 28/06/2021

 

Last updated on 23/07/2021